Abstract: This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.

Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.

Abstract: The present invention discloses methods for treating non-malignant cell diseases by administering to an individual a construct comprising actinium-225 or bismuth-213 and an antigen of a non-malignant cell. Also, provided is a method for treating a solid tumor associated with an abnormal proliferation of cells by targeting an antigen of the tumor-associated vasculature with the constructs.

Abstract: The present invention provides soluble single wall nanotube constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble single wall carbon nanotube via a DNA or other oligomer platform attached to the single wall carbon nanotube. These soluble single wall carbon nanotube constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble single wall carbon nanotube constructs.

Abstract: Eyeglasses comprising a frame (1) intended to support a pair of lenses (2) and having lateral ends (12) provided with slots (13), said frame (1) intended to be coupled to a retainer strap or band (3), with opposing free ends (5), which, when worn by the user around the head, allows him to wear the eyeglasses. A connecting member is provided (10) coupled to at least one of the free ends (5) of the aforementioned band (3), said connecting member (10) having an elongated body (15) with a portion (16) bent parallel to said body (15) and elastically movable in relation to it, said bent portion (16) intended to be inserted into one of the slots (13) provided on the lateral ends (12) of the frame (1) and being separable from it, deforming elastically if the band or strap (3) or the frame is subjected to tensile force.

Abstract: The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (>1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, including normal cells, that are targets for destruction, to achieve a therapeutic result. The alpha-emitting constructs have high specific activity.

Abstract: Aptamers and improved aptamers are provided with enhanced efficacy for binding to target molecules in vivo or for treating cancer or other diseases. Such improvements in aptamers are provided that enhance in vivo efficacy such as binding to the target molecule or enhancing anti-cancer activity. Such improvements also include stability to serum nucleases, reduced binding to a soluble form of the target molecule, increased avidity, affinity or specificity to the target molecule on a cell surface, increased lifetime in circulation, or any combination of the foregoing. Improvements are provided by truncation, multimerization, including at least one non-natural nucleic acid, adding a 3? or 5? polyethylene glycol, or any combination thereof. Aptamers for treatment of autoimmune diseases are also provided.

Abstract: Tolerance of the immune system for endogenous CD20 can be overcome and an immune response stimulated by administration of xenogeneic or xenoexpressed CD20 antigen. For example, mouse CD20, or antigenically-effective portions thereof, can be used to stimulate an immune response to the corresponding differentiation antigen in a human subject. Administration of xenogeneic antigens in accordance with the invention results in an effective immunity against CD20 expressed by the cancer in the treated individual, thus providing a therapeutic approach to the treatment of lymphomas and leukemia expressing CD20.

Abstract: A variable automotive passenger seating configuration including a first seating row having a first pair of spaced apart seats each having an interior side and an exterior side. A second seating row is provided including a second pair of spaced apart seats each having an interior side and an exterior side, and a movable center seat assembly is disposed between the interior sides of the second pair of seats. At least one of the first pair of seats includes a cut-out section adjacent the interior side and the center seat assembly is configured to correspond with the cut-out section and nest between the interior sides of the first pair of seats. The center seat assembly may be configured to enable the mounting of a rearward-facing infant car seat when in a folded position.

Abstract: The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (>1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, including normal cells, that are targets for destruction, to achieve a therapeutic result. The alpha-emitting constructs have high specific activity.

Abstract: The present invention is directed to a synthetic peptide comprising a sequence of amino acids containing at least a segment that is an analogue of a native peptide that specifically binds to HLA A0201 or HLA A0301 molecules on a cell characteristic of a pathophysiologic state in a mammal. The synthetic peptide may be derived form native peptides comprising a breakpoint region of the WT1 protein.

Abstract: The present invention provides the three-dimensional structure of human mitochondrial Homo sapiens peptide deformylase (HsPDF) protein, and HsPDF complexed to a binding compound, such as a PDF inhibitor. This crystallographic information will aid in the identification and development of novel binding compounds of HsPDF and other PDF family members which have anti-bacterial, anti-viral, anti-parasitical, anti-inflammatory, and/or anti-cancer activity.

Abstract: The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (>1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, including normal cells, that are targets for destruction, to achieve a therapeutic result. The alpha emitting constructs have high specific activity.

Abstract: This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.

Abstract: This invention provides peptides, immunogenic compositions and vaccines comprising same, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising same.

Abstract: The present invention provides compounds having formula (I): wherein W1, W2, R1, R3, R4, R2A and R2B are as defined herein. In another aspect, the invention provides an antibody or antibody fragment which binds specifically to a normal or transformed PSA glycan or glycopeptide of the invention.

Abstract: The present invention provides soluble single wall nanotube constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble single wall carbon nanotube via a DNA or other oligomer platform attached to the single wall carbon nanotube. These soluble single wall carbon nanotube constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble single wall carbon nanotube constructs.

Abstract: The present invention is directed to a synthetic peptide comprising a sequence of amino acids containing at least a segment that is an analogue of a native peptide that specifically binds to HLA A0201 or HLA A0301 molecules on a cell characteristic of a pathophysiologic state in a mammal. The synthetic peptide may be derived from native peptides comprising a breakpoint region of the WT1 protein.

Abstract: A variable automotive passenger seating configuration including a first seating row having a first pair of spaced apart seats each having an interior side and an exterior side. A second seating row is provided including a second pair of spaced apart seats each having an interior side and an exterior side, and a movable center seat assembly is disposed between the interior sides of the second pair of seats. At least one of the first pair of seats includes a cut-out section adjacent the interior side and the center seat assembly is configured to correspond with the cut-out section and nest between the interior sides of the first pair of seats. The center seat assembly may be configured to enable the mounting of a rearward-facing infant car seat when in a folded position.

Abstract: The present invention provides synthetic peptides comprising at least analogues of a native peptide that specifically bind to HLA A0201 or HLA A0301 molecules on a cell characteristic of a pathophysiologic state, such as a cancer cell, in a mammal. Also provided are pharmaceutical compositions and immunogenic compositions comprising at least the peptide analogue segments or a DNA encoding the same. Also provided are methods of using the synthetic peptides and immunogenic compositions to induce a heteroclitic immune response or to treat a cancer.